Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.

Timothy Anthony Yap Matthew G Krebs Sophie Postel-VinayAnthony El-KhouieryJean-Charles SoriaJuanita LopezAlienor BergesSy Amy CheungItziar Irurzun-AranaAndrew GoldwinBrunella FelicettiGemma N JonesAlan LauPaul FrewerAndrew J PierceGlen ClackChristine StephensSimon A SmithEmma DeanSimon J Hollingsworth

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The RP2D for ceralasertib plus carboplatin was established as ceralasertib 40 mg once daily on days 1-2 administered with carboplatin AUC5 every 3 weeks, with pharmacokinetic and pharmacodynamic studies confirming pharmacodynamic modulation and preliminary evidence of antitumor activity observed.

Keyphrases

phase ii study
phase iii
physical activity
open label
squamous cell carcinoma
locally advanced
radiation therapy
randomized controlled trial
preterm birth
dna damage
gestational age